Clinical Trials Sponsored by Horizon Therapeutics Ireland DAC

Total 19 results

Horizon Therapeutics Ireland DAC

Recruiting

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (N-MOmentum LT)

Neuromyelitis Optica Spectrum Disorder

Korea, Republic of, Hong Kong, Hungary, Thailand
Horizon Therapeutics Ireland DAC

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder

United Kingdom, Brazil, Serbia, United States, Canada, France, Poland, Spain, Sweden, Argentina, Netherlands
Horizon Therapeutics Ireland DAC

Recruiting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Idiopathic Inflammatory Myositis

Mexico, United States, Spain, Australia, Italy, United Kingdom, Czechia, Brazil, Germany
Horizon Therapeutics Ireland DAC

Recruiting

Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus (RECAST DLE)

Discoid Lupus Erythematosus

United States, Germany, Canada, France, Greece, Denmark, Brazil, Bulgaria, Czechia, Argentina, Poland
Horizon Therapeutics Ireland DAC

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Horizon Therapeutics Ireland DAC

Completed

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (MIRROR RCT)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Uncontrolled Gout | Kidney Transplant

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (MIRROR OL)

Gout

United States
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Sjogren's Syndrome
Horizon Therapeutics Ireland DAC

Recruiting

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Gout

United States
Horizon Therapeutics Ireland DAC

Recruiting

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

Israel, Chile, United States, Argentina, Canada, Japan, Korea, Republic of
Horizon Therapeutics Ireland DAC

Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy Related | Neuromyelitis Optica Spectrum Disorder

United States
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
Hansoh BioMedical R&D Company
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders

China
Horizon Therapeutics, LLC

Terminated

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) (THRIVE)

Urea Cycle Disorder

United States
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
Horizon Therapeutics, LLC

Completed

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder

United States, Spain, Italy, Switzerland
Horizon Therapeutics, LLC

Completed

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States, Canada

Clinical Trials Sponsored by Horizon Therapeutics Ireland DAC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations